Danaher Corp.

Danaher Corporation reported better than expected revenue, earnings, and cash flow for the second quarter of 2024.

The bioprocessing business showed sustained positive momentum, with orders increasing high single digits sequentially in Q2. However, bioprocessing demand in China remained weak due to liquidity management by customers.

In Life Sciences, capital equipment investments remained constrained, while recurring revenue was relatively stable. Academic markets were weaker, but applied markets performed comparatively better.